UNSPSC 51431703: Libenzapril

This classification denotes an ace inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QD8496WWYK. European Medicines Agency schedules Libenzapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08502MIG. Libenzapril generally arises in the molecular formula C18H25N3O5.

UNSPSC 51431703 Libenzapril is a Commodity code for prescription medications, and state and local governments use it to procure emergency and ongoing pharmaceutical supplies for fire rescue services, health agency programs, and distributed healthcare facilities. The recent opportunities show solicitations for advanced life support medications used directly by emergency responders, direct-to-manufacturer prescription fulfillment programs, and multi-source generic pharmaceuticals distributed through authorized wholesalers to state and local health systems. Issuing bodies include city fire departments (the City of Tampa), state health commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities including Oregon). Solicitations typically require vendors to meet FDA compliance, Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, and detailed product documentation with specific National Drug Codes (NDC), and to maintain expiration-date minimums of six to twelve months from manufacture.

Activity is concentrated in Texas, Minnesota, and Florida. The most recent opportunity is the City of Tampa's sealed-bid IFB (Solicitation 26P00188) due April 8, 2026, for four lines of advanced life support medications (Labetalol, Epinephrine, Adenosine, and Diltiazem) with an estimated contract value of $40,000.00 and a Small Local Business Enterprise (SLBE) 5 percent bid discount available. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, requiring vendors to distribute through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) and maintain commercial general liability insurance of $5,000,000 per occurrence. The Texas Health and Human Services Commission posted a Request for Information (RFI HHS0017013) due April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, with no award value specified at the exploratory stage.